Highlights
1 patent
About
Individualized Immunotherapy
Aummune is a clinical stage company developing a first-of-its-kind approach for individualized treatment of solid tumors. Its proprietary platform utilizes a unique efficacy-driven selection process to match and produce a patient-specific tri-functional oligonucleotide drug that safely and synergistically induces cancer cell death and activates both innate and adaptive immune responses.
Aummune’s lead program, AM003, has already initiated its Phase 1 clinical trial following successful demonstrations of efficacy and safety in multiple animal models. The company is now actively recruiting patients for this First-in-Human study, which targets those with locally advanced and metastatic solid tumors.
Identity
| Name | Aummune |
|---|---|
| Slug | aummune |
| Type / kind | startup |
| Crunchbase ID | aummune |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAoPq268QKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Weizmann St 6, Tel Aviv-Yafo, Israel |
Web & social
| Website | https://aummune.com |
|---|---|
| https://www.linkedin.com/company/79060359 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
immunotherapycancerprecision-medicinehealthcare-providersclinicspersonalized-medicinetreatmentspharmaceuticalscancer-therapy
Funding
| Total raised | — |
|---|---|
| Current stage | Seed |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}